Drug Trial Radar · NCT04589845
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
920
Planned (sponsor's estimate)
Start
Jan 18, 2021
Primary completion
Sep 25, 2032
Study completion Sep 25, 2032
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.
Conditions
- Solid Tumors
Interventions
EntrectinibDrug
Adults and pediatric participants with a BSA ≥1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 milligrams per square meter (mg/m\^2) (BSA=0.43-0.50 m\^2).
EntrectinibDrug
Adults and pediatric participants with a BSA ≥ 1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 mg/m\^2 (BSA=≤0.50 m\^2).
AlectinibDrug
Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules).
AtezolizumabDrug
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
IpatasertibDrug
For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
Trastuzumab emtansineDrug
Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
InavolisibDrug
GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
BelvarafenibDrug
Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
PralsetinibDrug
Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
DivarasibDrug
Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days).
CamonsertibDrug
Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)Time frame: Approximately up to 12 years
Locations
112 sites in 23 countries. Site status is shown where the registry gives one.
Western Regional Medical Center at Cancer Treatment Centers of America
Goodyear, Arizona
Kaiser Permanente Los Angeles
Los Angeles, California
USC Norris Cancer Center
Los Angeles, California
Hoag Memorial Hospital
Newport Beach, California
UC Davis Comprehensive Cancer Center
Sacramento, California
University Cancer & Blood Center, LLC
Athens, Georgia
St. Alphonsus
Boise, Idaho
Midwestern Regional Med Center
Zion, Illinois
Horizon Oncology Research, Inc.
Lafayette, Indiana
Maryland Hematology & Oncology. P.A.
Silver Spring, Maryland
Henry Ford Health System
Detroit, Michigan
Metro-Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
Billings, Montana
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
University of New Mexico
Albuquerque, New Mexico
Icahn School of Medicine at Mount Sinai
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Einstein Center for Cancer Care
The Bronx, New York
Barrett Cancer Center
Cincinnati, Ohio
Oncology Hematology Care Inc
Cincinnati, Ohio
Consultants in Medical Oncology and Hematology
Broomall, Pennsylvania
Alliance Cancer Specialists
Horsham, Pennsylvania
Virginia Cancer Specialists - Leesburg
Leesburg, Pennsylvania
Cancer Treatment Centers of America
Philadelphia, Pennsylvania
The West Clinic
Germantown, Tennessee
St. Jude Children'S Research Hospital
Memphis, Tennessee
Texas Oncology - Central South
Austin, Texas
Mary Crowley Medical Research Center
Dallas, Texas
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Texas Oncology- Northeast Texas
Tyler, Texas
Northwest Medical Specialties, PLLC
Tacoma, Washington
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin
Kinghorn Cancer Centre
Darlinghurst, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Royal Children's Hospital
Parkville, Victoria, Australia
Cliniques Universitaires St-Luc
Brussels, Belgium
GHdC Site Les Viviers
Charleroi, Belgium
UZ Antwerpen
Edegem, Belgium
UZ Gent
Ghent, Belgium
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.